Australian dementia experts push back on Cochrane Review, defending new treatments

ADNeT Director Chris Rowe argues the review’s methodology fundamentally skews its conclusions by grouping early experimental therapies, many of which failed to reduce amyloid in the brain, with newer, more advanced therapies that have demonstrated measurable biological and clinical effects. …